Development and Validation of a Radiomics-based Model to Predict Local Progression-free Survival After Chemo-radiotherapy in Patients With Esophageal Squamous Cell Cancer

He-San Luo (✉ luohesan@163.com)

Shantou Central Hospital

Ying-Ying Chen

Shantou Central Hospital

Sheng-Xi Wu

Shantou Central Hospital

Shao-Fu Huang

Shantou Central Hospital

Hong-Yao Xu

Shantou Central Hospital

Ren-Liang Xue

Shantou Central Hospital

Ze-Sen Du

Shantou Central Hospital

Xu-Yuan Li

Shantou Central Hospital

Lian-Xin Lin

Shantou Central Hospital

He-Cheng Huang

Shantou Central Hospital

Research

Keywords: Chemo-radiotherapy, esophageal squamous cell cancer, radiomics, LPFS, nomogram

Posted Date: June 14th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-577680/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose: To develop a nomogram model for predicting local progress-free survival (LPFS) in esophageal squamous cell carcinoma (ESCC) patients treated with chemoradiotherapy.

Methods: We collected the clinical data of ESCC patients treated with CCRT in our hospital. Eligible patients were randomly divided into training cohort and validation cohort. The least absolute shrinkage and selection operator (LASSO) with COX regression was performed to select optimal radiomics features calculating Rad-score for predicting LPFS in the training cohort. The univariate and multivariate analysis were performed to identify the predictive clinical factors for developing a nomogram model. The C-index was used to assess the performance of the predictive model and calibration curve was used to evaluate the accuracy.

Results: A total of 221 ESCC patients were included in our study, with 155 patients in training cohort and 66 patients in validation cohort. After LASSO COX regression analysis, seventeen radiomics features were selected to calculate Rad-score for predicting LPFS. The patients with a Rad-score ≥ 0.1411 had high risk of local recurrence, and those with a Rad-score < 0.1411 had low risk of local recurrence. Multivariate analysis showed that N stage, CR status and Rad-score were independent predictive factors for LPFS. A nomogram model was built based on the result of multivariate analysis. The C-index of the nomogram was 0.745 (95%CI: 0.7700-0.790) in training cohort and 0.723(95%CI: 0.654-0.791) in validation cohort. The 3-year LPFS rate predicted by the nomogram model was highly consistent with the actual 3-year LPFS rate both in the training cohort and the validation cohort.

Conclusion: We developed and validated a prediction model based on radiomics features and clinical factors, which can be used to predict LPFS of patients after CCRT. This model is conducive to making individualized chemoradiotherapy strategy and providing scientific basis for subsequent intensive adjuvant therapy for ESCC patients.

1. Introduction

Esophageal cancer (EC) is the sixth common malignant tumors in China with an estimated 477.9 thousand new cases, accounting for half of the new esophageal cancer worldwide(1, 2). In China, approximately 90% of the patients with esophageal cancer are esophageal squamous cell carcinomas (ESCC), which is different from esophageal adenocarcinoma (EAC) in risk factors and prognosis(3). Most patients diagnosed as locally advanced ESCC lost the opportunity for surgery, and concurrent chemoradiotherapy (CCRT) has been recommended as a standard treatment(4). However, more than a half of patients treated with standard dose CCRT eventually developed local recurrence or distant metastases and succumbed to this disease(5, 6). A personalized CCRT strategy with variable radiation dose based on PET-CT would benefit the patients with high tumor burden and risk of recurrence(7, 8). To facilitate a personalized CCRT strategy in an early stage, solid predictive model for local recurrence and prognosis before CCRT could play an important role.

For patients received CCRT, local and regional recurrence is the most primary failure pattern and pre-treatment clinical TNM staging is still the most commonly used system for prognosis prediction (9). However, the currently used clinical TNM staging adopts the same criteria as pathological staging, which is based on imaging assessment of tumor size and surrounding invasion, ignoring the information such as length and volume of esophageal cancer lesions. Recently, a series of clinicopathologic biomarkers have been investigated and verified to be used in prediction of therapeutic response and prognosis(10–12). Radiomics is a new technique for image quantitative analysis about computed tomography (CT) images, magnetic resonance (MR) images, positron emission tomography (PET) images, etc(13). Several studies demonstrated that radiomics features could potentially identify prognostic phenotype in patients with EC. Yip(14) et al suggested that a model combined CT-based texture feature and esophageal maximal wall thickness assessment could predict the overall survival in EC patients treated with CCRT. Moreover, the model performed better than treatment response alone. Larue(15) et al screened out five radiomics features from CT image before chemoradiotherapy to describe the heterogeneity of tumors and found that these five features could predict the 3-year survival rate of patients with EC after neo-chemoradiotherapy. However, most radiomic studies included a small number of investigated patients with EAC and ESCC.

In this study, we explored the prognostic value of 3D radiomics features in pretreatment CT images of esophageal cancer patients and developed a model containing radiomics features and clinical information to predict LPFS in patients with ESCC after CCRT. To evaluate the performance of the model, a validation cohort of patients were employed for validation.

2. Patients And Methods

2.1. Patients' cohort

We collected the clinical data of patients diagnosed as esophageal squamous cell carcinoma (ESCC) and received concurrent chemoradiotherapy (CCRT) in our hospital during the period from January 2013 to December 2015. Patients were excluded if they met the exclusion criteria as followed: 1) Patients received esophagectomy and preoperative or postoperative adjuvant radiotherapy; 2) Patients had distant metastatic disease; 3) Patients received low-dose (< 50Gy) palliative radiotherapy; 4) Clinicopathological information of the patients was incomplete; 5) Patients was diagnosed as esophageal fistula before treatment; 6) Poor visualization quality due to image artifacts or the tumor was too small to be recognized on CT images; 7) Patients had other primary tumor; 8) Patients died within three months after chemoradiotherapy.

After multiple iterations, a total of 221 patients were randomly divided into two groups, with 155 patients in the training cohort and 66 patients in the validation cohort. To improve the generalization property of the result, multi-factors stratification was used to keep the characteristics of sub cohort consistent with the whole cohort. The process of patients' enrollment and randomization were shown in Fig. 1. This study

was approved by the Institutional Committee of our hospital on Human Rights. Disease of the patients was staged according to the 8th edition of AJCC TNM classification for esophageal cancer(16).

2.2. Chemoradiotherapy protocol

Radiotherapy was delivered daily to patients with three-dimensional conformal radiation therapy (3DRT) or intensity-modulated radiation therapy (IMRT) technique using a Varian IX or Varian 23EX linear accelerator in this study. The gross tumor volume (GTV) includes the esophageal cancer (GTVp) and the positive regional lymph nodes (GTVnd). The GTV was delineated on CT imaging according to barium esophagogram, endoscopic examination or PET imaging. The CTV is defined as the GTVp with 0.5 to 1 cm radial expansion and 2.5 to 3 cm axial direction expansion or the GTVnd with 0.5 to 0.8 cm uniform expansion. The planning target volume (PTV) was defined as CTV with a 1cm uniform expansion. A total prescribed dose of 50–72 Gy (median, 64Gy) in conventional fractionation was delivered to the patients.

Two cycles of platinum-based chemotherapy were administered concurrently with radiotherapy. Sixty-one patients received TP (paclitaxel + cisplatin) chemotherapy every three weeks, which consists of cisplatin (60 mg/m² on Day 1) plus paclitaxel (135–180 mg/m² on Days 1). One hundred and sixty patients received the PF (cisplatin + fluorouracil) regimen every four weeks, which consists of cisplatin (60 mg/m² on Day 1) and fluorouracil (750 mg/m² /24 h on Days 1 to 4).

2.3. Response evaluation

The response to chemoradiotherapy was evaluated one month after CRT according to the criteria of short-term response evaluation standard on esophageal cancer using CT images and barium esophagogram. According to the response evaluation criteria, clinical response was classified as complete response (CR), partial response (PR), no response (NR), or progressive disease (PD). Patients who was classified as CR by barium esophagogram and had the maximal esophageal wall thickness of ≤ 1.2 cm and the volumes of residual lymph nodes of ≤ 1.0 cm³ on CT were finally defined as CR(17).

2.4. Radiomic feature extraction

All patients were scanned using GE Lightspeed 64-slice spiral CT (GE Medical systems, Milwaukee, Wis) before radiotherapy. CT image acquisition was performed according to the following acquisition protocol: The CT tube voltage was 120 kV and the tube current was 120 mAs. Rack rotation time: 0.6s; Detector collimation parameters: 64×0.625mm; field of view (FOV): 400-500mm; Matrix: 512×512; Layer thickness is 5mm, layer spacing is 5mm. Contrast medium was injected with a high-pressure syringe at a flow rate of 3.0 ml/s (1-1.5ml/kg, ioproxamine injection 300), followed by 30 to 40 ml of normal saline for flushing, and late arterial CT images were collected with a delay of 30s. To reduce the variability between images from different patients, all images were resampled to voxel of 1*1*1mm³.

3D Slicer (version, 4.10.2, Stable Release) with radiomics extension was used for image segmentation to obtain volume of interest (VOIs). The primary tumor volume (GTV) delineated by radiation oncologists for radiotherapy treatment planning design was defined as VOI for radiomics features extraction. Any pixel

with an attenuation of less than – 50 HU was excluded to avoid adjacent air, fat, blood vessels and surrounding organs. Image segmentation was performed independently by a radiation oncologist and another radiologist. To assess the reproducibility of the radiomics features extraction, tumor segmentation was performed again two months later by the same radiologist in 30 randomly chosen patients.

Pyradiomics V3.6.2 was used to extract radiomic features from delineated VOIs. Several category features were extracted from VOIs, including first order statistics features (IH, intensity histogram), shape-based histogram features, and texture features (gray-level co-occurrence matrix, GLCM; gray-level size-zone matrix, GLSZM; gray-level run-length matrix, GLRLM; neighboring gray-tone difference matrix, NGTDM; and gray-level dependence matrix, GLDM). The wavelet filter was used in image pre-processing for texture features extraction. In all, for each VOI, 107 original features (Supplemental Table 1) and 744 wavelet features (Supplemental Table 1) were collected. Among 107 original features, there were 18 first order statistics features, 14 shape-based histogram features, 24 GLCM features, 14 GLDM features, 16 GLRLM features, 16 GLSZM features and 5 NGTDM features. Mathematical definitions of these radiomic features have previously been described(18) and available at <https://pyradiomics.readthedocs.io/en/latest/features.html>.

2.5. Statistical analysis

At the first, statistical analyses were performed with Chi-squared test or Fisher's to assess the difference of the clinical characteristics between training cohort and validation cohort. A P-value of < 0.05 was considered statistically significant.

In the pre-processing of radiomics features, all the radiomic features values were normalized using Z-score normalization, which made feature values lie within similar ranges and reduced the influence large discrete features values. The intra-class correlation coefficient (ICC) analysis was performed to evaluate the reproducibility of each radiomics feature. Only the features with ICCs value ≥ 0.900 were selected for further analysis. Then, the least absolute shrinkage and selection operator (LASSO) with COX regression was performed using R software version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria) to identify the features associated with LPFS in the training cohort. The optimal parameter lambda (λ) was chosen from the LASSO model using 10-fold cross-validation with the minimum partial likelihood deviance. Radiomics feature score (Rad score) for each patient was built based on the LASSO COX regression model in the training cohort. The LASSO COX regression formula:

$$\text{Rad score} = \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3 + \dots + \beta_n X_n$$

In the above formula, $X_1, X_2 \dots X_n$ are the different radiomics features identified by the LASSO COX regression model, and $\beta_1, \beta_2 \dots \beta_n$ are the regression coefficients of the corresponding feature in the regression model.

Univariate analysis was performed to identify the potential prognostic factors associated with LPFS. Multivariable COX regression analysis was performed to identify the independently predictors for LPFS. A

nomogram model combined Rad-score and clinical factors for predicting LPFS was developed and validated based on the results of multivariable COX regression analysis using rms package and foreign package in R software. The predictive performance of the nomogram model was assessed using Calibration curve validation in both training cohort and validation cohort. All the analyses were performed with R software version 3.6.2.

3. Results

3.1. Patients' Characteristics

A total of 221 ESCC patients who received chemoradiotherapy in our hospital were eligible for further analysis in this study. Patients' characteristics are summarized in Table 1. The median follow-up time was 18.6 months. By the end of the last follow-up, 153 patients developed local regional disease progression or died. The median LPFS in the whole group was 13.7 months, and the rates of 1-year, 2-year and 3-year LPFS were 56.1%, 37.4% and 32.1%, respectively(Fig. 2).

Table 1
Comparison of patients' characteristics between training cohort and validation cohort

Variables	Training cohort(n = 155)	Validation cohort(n = 66)	χ^2 / t	<i>P</i>
Age (years),Mean $\pm$ SD	65.7147 $\pm$ 9.74	64.73 $\pm$ 10.16	0.678	0.499
Gender			0.342	0.559
Male	116(74.8)	45(68.2)		
Female	39(25.2)	21(31.8)		
Tumor location			5.814	0.121
Cervical	6(3.9)	8(12.1)		
Upper thoracic	34(21.9)	16(24.2)		
Middle thoracic	91(58.7)	33(50.00)		
Lower thoracic	24(15.5)	9(13.6)		
T stage			3.193	0.363
T1	2(1.3)	0(0)		
T2	11(7.1)	9(13.6)		
T3	66(42.6)	27(40.9)		
T4	76(49.0)	30(45.5)		
N stage			1.856	0.603
N0	20(12.9)	13(19.7)		
N1	70(45.2)	28(42.4)		
N2	55(35.5)	22(33.3)		
N3	10(6.5)	3(4.5)		
Clinical stage			3.152	0.369
I	2(1.3)	0(0)		
II	15(9.7)	11(16.7)		
III	88(56.8)	37(56.1)		
Iva	50(32.3)	18(27.3)		
Radiation dose,Median(range)	64(60–66)	64(60–66)	-0.920	0.358
LDH group			1.282	0.258

Variables	Training cohort(n = 155)	Validation cohort(n = 66)	χ^2 / t	<i>P</i>
High	88(56.8)	32(48.5)		
Normal	67(43.2)	34(51.5)		
NLR,Median(range)	2.73(1.96–3.71)	2.76(2.00-3.63)	-0.448	0.654
PLR,Median(range)	137.78(100.56-181.43)	138.87(101.31-182.26)	-0.344	0.731
CR ratio	52(33.5)	26(39.4)	0.693	0.405
Rad-score,Mean $\pm$ SD	-0.0289 $\pm$ 0.35	-0.058 $\pm$ 0.538	0.474	0.636

In order to develop and validation a radiomics-based model for predicting LPFS of the patients, they were randomly divided into training cohort and validation cohort. There are 155 patients enrolled in the training cohort and 66 patients in the validation cohort. There were no significant differences in the distribution of baseline characteristics such as age, gender, tumor location, T stage, N stage, clinical staging, lactate dehydrogenase (LDH), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and CR ratio (33.5% in the training cohort vs 39.4% in the validation cohort). The results were not statistically significant ($p > 0.05$), and the two groups of patients were comparable.

3.2. Rad-score building based on radiomics features

LASSO-COX regression was used to pick out the optimal radiomics features associated with LPFS of the patients in the training cohort (Fig. 3A and B). As a result, seventeen radiomics features were picked out (The features and their coefficients were listed in the Table 2). The Rad-score was calculated as follows:
Rad-score=-0.104667846*original_firstorder_Skewness +
0.001161134*origin_glszm_SizeZoneNonUniformityNormalized +
0.034339901*origin_glszm_SizeZoneNonUniformity-
0.017089976*origin_glszm_LowGrayLevelZoneEmphasis + 0.062595767*wavelet-HLL_glcmln +
0.026703955*wavelet-HLL_firstorder_Maximum + 0.042957143*wavelet-
HLL_glszm_SizeZoneNonUniformityNormalized + 0.017543973*wavelet-LHL_firstorder_TotalEnergy +
0.003781538*wavelet-LHL_firstorder_Maximum-0.007364328*wavelet-
LLH_gldm_SmallDependenceLowGrayLevelEmphasis + 0.157807433*wavelet-
LLH_glcmln_DifferenceVariance + 0.042028490*wavelet-LLH_gldm_ShortRunHighGrayLevelEmphasis-
0.101981005*wavelet-LLH_ngtdm_Coarseness-0.073958943*wavelet-
HLH_gldm_SmallDependenceLowGrayLevelEmphasis + 0.051287394*wavelet-HLH_firstorder_Maximum-
0.055239045*wavelet-HHH_glcmln_MaximumProbability-0.028958889*wavelet-LLL_glcmln_Imc2.

Table 2
Radiomics feature associated with LPFS selected by LASSO COX analysis

Radiomics features	coefficients
original_firstorder_Skewness	-0.104667846
origin_glszm_SizeZoneNonUniformityNormalized	0.001161134
origin_glszm_SizeZoneNonUniformity	0.034339901
origin_glszm_LowGrayLevelZoneEmphasis	-0.017089976
wavelet-HLL_glcmln	0.062595767
wavelet-HLL_firstorder_Maximum	0.026703955
wavelet-HLL_glszm_SizeZoneNonUniformityNormalized	0.042957143
wavelet-LHL_firstorder_TotalEnergy	0.017543973
wavelet-LHL_firstorder_Maximum	0.003781538
wavelet-LLH_gldm_SmallDependenceLowGrayLevelEmphasis	-0.007364328
wavelet-LLH_glcmln_DifferenceVariance	0.157807433
wavelet-LLH_gldm_ShortRunHighGrayLevelEmphasis	0.042028490
wavelet-LLH_ngtdm_Coarseness	-0.101981005
wavelet-HLH_gldm_SmallDependenceLowGrayLevelEmphasis	-0.073958943
wavelet-HLH_firstorder_Maximum	0.051287394
wavelet-HHH_glcmln MaximumProbability	-0.055239045
wavelet-LLL_glcmln_lmc2	-0.028958889

There was an optimal cutoff value of Rad score to divide the patients into two groups with different risk of local recurrence. As shown in Fig. 3C, the patients with a Rad-score ≥ 0.1411 had high risk of local recurrence, and those with a Rad-score < 0.1411 had low risk of local recurrence. In the training cohort, the patients in the group with high risk of local recurrence had a significant short LPFS than those in the low risk of local recurrence (Fig. 4A, HR: 2.882, 95%CI: 1.926–4.313, $P < 0.001$). The same result can be seen in the validation cohort (Figure 4B, HR: 1.997, 95%CI: 1.070–3.728, $P = 0.026$).

3.4. Development and validation of a predictive nomogram based on Rad-score

In order to develop a model to predict LRFS based on multiple factors, we performed univariate and multivariate analyses to identify predictive factors for LPFS. Univariate analysis showed that the T stage,

N stage, clinical stage and CR status were significantly associated with LPFS both in training cohort and validation cohort (Table 3). Multivariate analysis showed that N stage, CR status and Rad score were independent predictive factors for LPFS in ESCC patients after chemoradiotherapy (Table 4). A nomogram model for predicting LPFS was built based on the result of multivariate analysis (Fig. 5A). As shown in Fig. 5, 1-year, 2-year and 3-year LPFS rate of each patients could be predicted based on the independent clinical characteristics and Rad score. The C-index of the nomogram was 0.745 (95%CI: 0.7700–0.790) in training cohort and 0.723(95%CI: 0.654–0.791) in validation cohort.

Table 3
Univariate analysis of prognostic factors associated with LPFS in patients with ESCC treated with chemoradiotherapy

variables	Training cohort			Validation cohort		
	HR	95%CI	<i>P</i>	HR	95%CI	<i>P</i>
Age	0.987	0.967–1.007	0.202	0.984	0.957–1.011	0.252
Gender	1.639	1.014–2.650	0.044	1.198	0.652–2.202	0.560
Tumor location	1.120	0.851–1.473	0.419	1.289	0.917–1.812	0.143
T stage	2.015	1.453–2.793	< 0.001	1.943	1.227–3.077	0.005
N stage	1.867	1.446–2.410	< 0.001	1.765	1.215–2.563	0.003
Clinical stage	2.194	1.581–3.044	< 0.001	2.309	1.440–3.704	0.001
Radiation dose	0.965	0.923–1.009	0.118	0.996	0.921–1.078	0.927
LDH	1.641	1.116–2.414	0.012	1.369	0.778–2.408	0.276
NLR	1.069	0.965–1.184	0.199	1.015	0.901–1.142	0.810
PLR	1.001	0.999–1.003	0.177	1.001	0.999–1.004	0.377
CR status	0.128	0.072–0.228	< 0.001	0.295	0.157–0.556	< 0.001

Table 4
Multivariate analysis of prognostic factors
associated with LPFS for patients with ESCC
treated with chemoradiotherapy

Variables	Multivariate analysis		
	HR	95%CI	<i>P</i>
T stage	0.858	0.526-1.400	0.540
N stage	1.892	1.122–3.190	0.017
Clinical stage	0.627	0.313–1.258	0.189
Rad-score	4.423	1.993–9.814	0.000
CR status	0.154	0.080–0.297	0.000

Finally, we performed calibration curve to evaluate the nomogram model. As shown in Fig. 6, the 3-year LPFS rate predicted by the nomogram model based on Rad-score was highly consistent with the actual 3-year LPFS rate both in the training cohort and the validation cohort.

4. Discussion

Concurrent chemoradiotherapy (CCRT) is a radical treatment for patients with inoperable esophageal cancer or refused surgery(4). Many studies have shown that dose-escalation radiotherapy properly can improve the local control and survival of patients with ESCC(19–22). Nevertheless, 30–50% of patients have local recurrence within 3 years(23–25). In our present study, we constructed a prediction model combined the clinical characteristics and the pretreatment CT radiomics features that can predict the LPFS of patients after CCRT. Through this model, we can preliminarily judge the probability of LPFS of patients, thus providing evidence for strengthening the individualized treatment plan of patients.

Radiomics studies in esophageal cancer started late, and there are still few data about applying radiomics analysis to evaluate the prognosis of esophageal cancer. Ganeshan et al(26) first analyzed the radiomics features of CT before treatment in esophageal cancer patients and found that the radiomics features representing uniformity parameters were significantly different in stage I/II and stage III/IV disease, which were independent predictors of patients' prognosis. Subsequently, Yip et al(14) found that the tumor heterogeneity could be represented by the change of CT radiomics features before and after neoadjuvant treatment, which was related to the prognosis and survival of patients. Larue et al(15) also found that five radiomics features extracted from CT before chemoradiotherapy could be used to describe the tumor heterogeneity and predict the 3-year survival rate of patients after neoadjuvant chemoradiotherapy and surgery with AUCs(AUC, area under the receiver) of 0.69 in the training group and 0.61 in the validation group. All these studies suggest that radiomics features play an important role in evaluating the prognosis of esophageal cancer, so as to predict the long-term survival of esophageal

cancer patients after chemoradiotherapy. In this present study, we screened out 17 radiomics features that may be related to LPFS after CCRT and constructed a nomogram model combined radiomics features and other clinical features which can be used to predict LPFS of patients.

Clinical TNM staging before treatment is still the most commonly used prediction system for evaluating the prognosis of ESCC patients after chemoradiotherapy. Combination of TNM staging and other prognostic factors can predict the prognosis of patients more individually and accurately(27, 28). Some studies have shown that the prognosis of patients achieved CR after chemoradiotherapy was better than that of patients not CR(29, 30). Therefore, CR after CCRT had become another important predictor for the prognosis of patients besides clinical stages. In the present study, univariate analysis showed that pre-treatment clinical T stage, N stage, clinical stage and CR after radiotherapy were the prognostic factors related to LPFS after chemoradiotherapy. Moreover, Rad-score based on 17 radiomics features extracted from CT images before chemoradiotherapy was significantly related to LPFS of patients after chemoradiotherapy. Further multivariate analysis showed that Rad-score, N stage and CR after radiotherapy were independent predictors of patients' LPFS, while T stage and clinical stage had no statistical significance in this multivariate analysis model, probably because Rad-score came from the primary tumor focus and had interactive effects with T stage and clinical stage. We established and validated a nomogram model based on the results of multivariate analysis. C-index and calibration curve were used to evaluate the prediction accuracy of the nomogram model. The C-index of the model was 0.745(95%CI:0.700–0.790) in the training cohort and 0.723(95%CI:0.654–0.791) in the validation cohort, indicating high prediction accuracy. The calibration curve also demonstrated the same result. Therefore, we believe that this prediction model based on Rad-score can provide a more accurate tool to predict LPFS, which was a convenient and economical means.

Although we had established and validated a prognosis prediction model based on CT radiomics features before treatment, there are inevitably some defects in this study. First of all, this study is a retrospective study. Because of the long-time span of CT images used in image data acquisition, there were inevitably some problems that the image quality and scanning parameters were hard to be exactly the same, especially the development time and dosage of enhancer, so this study only collects the information of plain CT images. Secondly, as response of patients treated with chemoradiotherapy could not be evaluated pathologically, clinical CR used in our study can't truly represent pathological CR completely and accurately. Fortunately, a considerable number of patients achieved CR had been confirmed by gastroscopy pathology. Being limited by the nature of a single-center retrospective study, the results may be biased to some extent, and its reliability and universality still need different centers to further carry out large sample research verification.

Conclusion

In a word, this study established and validated a prediction model based on radiomics features and clinical factors, which can be used to predict LPFS of patients after CCRT. As an intuitive and convenient

prediction method, this model is conducive to making individualized chemoradiotherapy strategy for ESCC patients and providing scientific basis for subsequent intensive adjuvant therapy.

Abbreviations

ESCC: esophageal squamous cell cancer; CCRT: concurrent chemo-radiotherapy; CR: complete response; LPFS: local progress-free survival; LASSO: least absolute shrinkage and selection operator; AUC: area under the receiver; EC: esophageal cancer; CT: computed tomography; MR: magnetic resonance; 3DRT: three-dimensional conformal radiation therapy; GTV: gross tumor volume; GTVnd: nodal gross tumor volume; CTV: clinical target volume; CTVt: tumor clinical target volume; CTVnd: nodal clinical target volume; PTV: planning target volume; VOI: volume of interest; GLCM: gray-level co-occurrence matrix; GLSZM: gray-level size-zone matrix; GLRLM: gray-level run-length matrix; NGTDM: neighboring gray-tone difference matrix; GLDM: gray-level dependence matrix.

Declarations

Funding

None.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contribution

He-San Luo designed the study. He-San Luo and Ying-Ying Chen prepared figures and wrote the manuscript text. Hong-Yao Xu, Ren-Liang Xue, and Shao-Fu Huang collected the follow-up data. Sheng-Xi Wu, Ze-Sen Du and Xu-Yuan Li made statistical analysis. All authors reviewed the manuscript and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

Authors declare that there is no conflict of interest.

Acknowledgement

None.

References

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115-32. doi:10.3322/caac.21338
2. Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. *Journal of surgical oncology*. 2017;115(5):564-79. doi:10.1002/jso.24592
3. Zeng H, Zheng R, Zhang S, et al. Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. *Thoracic cancer*. 2016;7(2):232-7. doi:10.1111/1759-7714.12322
4. Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2019;17(7):855-83. doi:10.6004/jnccn.2019.0033
5. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. *J Clin Oncol*. 2002;20(5):1167-74. doi:10.1200/JCO.2002.20.5.1167
6. Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. *Cancer*. 2012;118(10):2632-40. doi:10.1002/cncr.26586
7. Li Y, Zschaek S, Lin Q, Chen S, Chen L, Wu H. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation. *Radiation oncology*. 2019;14(1):35. doi:10.1186/s13014-019-1236-x
8. Nkhali L, Thureau S, Edet-Sanson A, et al. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses. *Acta oncologica*. 2015;54(6):909-15. doi:10.3109/0284186X.2014.973062
9. Wang WP, He SL, Yang YS, Chen LQ. Strategies of nodal staging of the TNM system for esophageal cancer. *Annals of translational medicine*. 2018;6(4):77. doi:10.21037/atm.2017.12.17
10. Luo HS, Xu HY, Du ZS, et al. Impact of sex on the prognosis of patients with esophageal squamous cell cancer underwent definitive radiotherapy: a propensity score-matched analysis. *Radiation oncology*. 2019;14(1):74. doi:10.1186/s13014-019-1278-0
11. Yang Z, He B, Zhuang X, et al. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. *J Radiat Res*. 2019;60(4):538-45. doi:10.1093/jrr/rrz027
12. Hu P, Liu Q, Deng G, et al. Radiosensitivity nomogram based on circulating neutrophils in thoracic cancer. *Future Oncol*. 2019;15(7):727-37. doi:10.2217/fon-2018-0398
13. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer*. 2012;48(4):441-6.

14. Yip C, Landau D, Kozarski R, et al. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. *Radiology*. 2014;270(1):141-8. doi:10.1148/radiol.13122869
15. Larue R, Klaassen R, Jochems A, et al. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. *Acta oncologica*. 2018;57(11):1475-81. doi:10.1080/0284186X.2018.1486039
16. Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin*. 2017;67(4):304-17. doi:10.3322/caac.21399
17. Chun H, Xue-jiao R, Lan W, Chao G, Gao-feng S, Guang-da W. Evaluating short-term radiotherapeutic effect on esophageal cancer by barium meal combined with CT scans. *Chinese Journal of Radiation Oncology*. 2013;22(1):26-9.
18. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational Radiomics System to Decode the Radiographic Phenotype. *Cancer Res*. 2017;77(21):e104-e7. doi:10.1158/0008-5472.CAN-17-0339
19. Li C, Ni W, Wang X, et al. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. *Radiation oncology*. 2019;14(1):48. doi:10.1186/s13014-019-1249-5
20. Lin FC, Chang WL, Chiang NJ, et al. Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy. *PloS one*. 2020;15(8):e0237114. doi:10.1371/journal.pone.0237114
21. Zhang W, Luo Y, Wang X, et al. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. *Cancer management and research*. 2018;10:2675-82. doi:10.2147/CMAR.S160909
22. Zhang W, Zhao J, Han W, et al. Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). *Annals of translational medicine*. 2020;8(18):1140. doi:10.21037/atm-20-4672
23. Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. *J Clin Oncol*. 2014;32(5):385-91. doi:10.1200/JCO.2013.51.2186
24. Zhou S, Zhang L, Luo L, et al. Failure pattern of elective nodal irradiation for esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy. *Japanese journal of clinical oncology*. 2018;48(9):815-21. doi:10.1093/jjco/hyy099
25. Zhu SC, Li QF, Zhang XY, et al. [Clinical outcomes of different irradiation ranges in definitive intensity-modulated radiotherapy for esophageal cancer]. *Zhonghua zhong liu za zhi [Chinese journal of oncology]*. 2020;42(12):1040-7. doi:10.3760/cma.j.cn112152-20191225-00842
26. Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour

- metabolism, stage, and survival. Clin Radiol. 2012;67(2):157-64. doi:10.1016/j.crad.2011.08.012
27. Zhang X, Wang Y, Qu P, et al. Prognostic Value of Tumor Length for Cause-Specific Death in Resectable Esophageal Cancer. Ann Thorac Surg. 2018;106(4):1038-46. doi:10.1016/j.athoracsur.2018.05.018
28. Zhiguo Z, Xin W, Lan W, et al. Effect of tumor length on clinical stage for non-operative esophageal squamous cell carcinoma patients—multicenter retrospective data analysis (3JECROG R-01D). Chinese Journal of Radiation Oncology. 2019;28(7):490-4. doi:10.3760/cma.j.issn.1004-4221.2019.07.003
29. Liu SL, Xi M, Yang H, et al. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer? Ann Surg Oncol. 2016;23(1):273-81. doi:10.1245/s10434-015-4764-0
30. Li Z, Shan F, Wang Y, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PloS one. 2018;13(1):e0189294. doi:10.1371/journal.pone.0189294

Supplementary Table

Supplementary Table 1 is not available with this version.

Figures

Figure 1

Flow chart of patients' screening and allocation.

Figure 2

Kaplan-Meier curve of local-progression free survival for all patients.

Figure 3

Selection of radiomics features associated with LPFS using the LASSO COX regression model. A. Coefficients profiles of radiomics features. The horizontal axis value is $\log \lambda$, and the vertical axis value represent the coefficients of radiomics features. B. The cross-validation curve. The horizontal axis value is $\log \lambda$, and the vertical axis value is partial likelihood deviance. C. The optimal cutoff of Rad-score. Red lines or red dots represent patients at high risk of local recurrence and blue lines or blue dots represent patients at low risk of local recurrence. The optimal cutoff value is 0.1411, as shown in the vertical line in the figure.

A

Survival probability

B

Survival probability

Figure 4

Kaplan-meier survival curve of patients with high and low recurrence risk based on Rad-score. A. LPFS survival curve of patients in the training cohort: green line represents patients with low risk of local recurrence and red represents patients with high risk of local recurrence. The difference is significant between two groups, $p < 0.001$. B. LPFS survival curve of patients in the validation cohort: green line

represents patients with low risk of local recurrence and red line represents patients with high risk of local recurrence. The difference is significant between two groups, $p=0.026$.

Figure 5

Nomogram model for predicting LPFS based on Rad-score. Rad. score refers to Rad-score. 0, 1, 2, and 3 refers to N0, N1, N2 and N3 in N stage line respectively. CR represents complete response, the value of 0 and 1 refer to non-CR and CR status respectively.

Figure 6

Calibration curve validation for Nomogram model in training cohort (A) and validation cohort (B). The horizontal axis represents the predicted 3-year LPFS and the vertical axis represents the actual 3-year LPFS. The blue diagonal dot line represents the ideal nomogram, and the red line represents the observed nomogram. The closer the calibration curve is to the diagonal line, the higher the consistency between the predicted results and the actual situation.